MAIA Biotechnology, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity - Additional Information (Details)

Stockholders' Equity - Additional Information (Details) - USD ($)		1 Months Ended		2 Months Ended	3 Months Ended				6 Months Ended
	Aug. 13, 2021	May 31, 2022	Jan. 31, 2022	Feb. 28, 2022	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Jul. 31, 2021	Dec. 31, 2020	Nov. 30, 2020	Mar. 31, 2020
Subsidiary or Equity Method Investee [Line Items]
Common stock, shares authorized					30,000,000				30,000,000		30,000,000				100,000,000
Common stock, par value					$ 0.0001	$ 0.0001			$ 0.0001		$ 0.0001				$ 0.0001
Preferred stock, shares issued					0				0		0				70,000,000
Preferred stock, par value					$ 0.0001				$ 0.0001		$ 0.0001				$ 0.0001
Common stock, shares issued					8,416,032				8,416,032		7,584,980				30,000,000
Number of common stock sold		11,111		263,729
Sale of common stock, price per share		$ 9		$ 9
Common stock per share		$ 9.00		$ 9.00		$ 9.00
Gross proceeds from sale of common stock		$ 99,999		$ 2,373,561					$ 2,473,561
Transaction costs		$ 0		$ 0
Stock compensation expense					$ 584,768		$ 777,132		1,298,098	$ 1,330,324
Deemed dividend on warrant modification									$ (450,578)
Warrants exercised, shares		394,501
Cashless exercise at fair market value per share		$ 9
Issuance of common shares upon cashless exercise of warrants, shares		315,601
Stock options outstanding					5,927,523				5,927,523		5,797,185
Fair value assumptions, contractual term									7 years
Exercise price percentage									110.00%
Percentage of shares granted									10.00%
January 1 to January 26, 2022 [Member]
Subsidiary or Equity Method Investee [Line Items]
Common stock, par value					$ 8.87				$ 8.87
January 27 to June 30, 2022 [Member]
Subsidiary or Equity Method Investee [Line Items]
Sale of common stock, price per share					$ 9				$ 9
January 1, 2021 to February 28, 2021 [Member]
Subsidiary or Equity Method Investee [Line Items]
Sale of common stock, price per share							$ 1.80			$ 1.80
March 1, 2021 to June 6, 2021 [Member]
Subsidiary or Equity Method Investee [Line Items]
Sale of common stock, price per share							$ 1.83			$ 1.83
Maximum
Subsidiary or Equity Method Investee [Line Items]
Fair value assumptions, contractual term									10 years
2018 Stock Option Plan
Subsidiary or Equity Method Investee [Line Items]
Common stock reserved for issuance					3,900,000				3,900,000
Stock options outstanding					1,934,500				1,934,500
Amended and Restated 2020 Equity Incentive Plan
Subsidiary or Equity Method Investee [Line Items]
Common stock reserved for issuance					174,977				174,977			4,171,000	1,671,000	3,171,000
Stock options outstanding					3,993,023				3,993,023
IPO
Subsidiary or Equity Method Investee [Line Items]
Common stock per share				$ 5.00
Common Stock
Subsidiary or Equity Method Investee [Line Items]
Number of common stock sold		11,111		263,729
Sale of common stock, price per share		$ 9		$ 9.00
Issuance of restricted common shares, Shares								15,278
Issuance of common shares upon exercise of warrants, Shares		153,000	61,111		468,601	61,111
Proceeds from issuance of common stock upon exercise of warrants		$ 275,400	$ 110,000
Founder
Subsidiary or Equity Method Investee [Line Items]
Stock compensation expense										$ 135,000
Issuance of restricted common shares, Shares										87,500
Restricted Stock Awards
Subsidiary or Equity Method Investee [Line Items]
Founders shares vested									58,333
Unvested shares					0				0		58,333
Restricted Stock Awards \| Founder
Subsidiary or Equity Method Investee [Line Items]
Stock compensation expense										$ 105,000
Shares granted										75,000
Additional incremental stock compensation										$ 0
MAIA Stock Warrants
Subsidiary or Equity Method Investee [Line Items]
Warrant modification, value			$ 144,497
Deemed dividend on warrant modification						$ 450,578
Stock Options
Subsidiary or Equity Method Investee [Line Items]
Weighted-average grant date fair value									$ 5.97	$ 1.49
Unrecognized compensation					$ 2,991,036				$ 2,991,036
Unrecognized compensation expense, recognized period									3 years 1 month 6 days
Stock Options \| Maximum
Subsidiary or Equity Method Investee [Line Items]
Fair value assumptions, contractual term									6 years 3 months	6 years 6 months
Stock Options \| Minimum
Subsidiary or Equity Method Investee [Line Items]
Fair value assumptions, contractual term									5 years	5 years
T H I O \| Founder
Subsidiary or Equity Method Investee [Line Items]
Issuance of restricted common shares, Shares	612,500
T H I O \| Restricted Stock Awards \| Founder
Subsidiary or Equity Method Investee [Line Items]
Founders shares vested	612,500
Founders shares cancelled	612,500